Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study

Machytka, Evžen; Chuttani, Ram; Bojková, Martina; Kupka, Tomáš; Bužga, Marek; Stecco, Kathryn; Lévy, Samuel; Gaur, Shantanu

doi:10.1007/s11695-015-1783-7

Cited by 57 publications

(28 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At 6 weeks, the mean %EWL was 12.4%. One patient had the balloon endoscopically punctured owing to partial collapse, and one patient elected to have the balloon endoscopically removed; however, no serious adverse events occurred …”

Section: Space‐occupying Devicesmentioning

confidence: 82%

Endoluminal weight loss and metabolic therapies: current and future techniques

Hill

Khashab

Kalloo

et al. 2017

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

Obesity is a public health epidemic associated with a number of comorbidities, most notably type 2 diabetes and hypertension, as well as elevated all-cause mortality. The treatment for obesity and its associated comorbidities has most recently expanded into the field of bariatric endoscopy. This field bridges a gap between lifestyle counseling with or without pharmaceutical treatment and the most effective treatment of obesity, bariatric surgery. Because of its minimally invasive nature, bariatric endoscopic therapy has the potential to appeal to the large sector of the obese population that resists surgery, as well as those early in the onset of obesity. To date, five endoscopic devices have been approved by the U.S. Food and Drug Administration for the treatment of obesity, and many more are in development, undergoing clinical trials, or being used around the world. Here, we present the current state of the field, highlight recent developments, and describe the clinical outcomes of these minimally invasive procedures in terms of weight loss, improvement in metabolic profile, and reduction in comorbidities.

show abstract

Section: Space‐occupying Devicesmentioning

confidence: 82%

Endoluminal weight loss and metabolic therapies: current and future techniques

Hill

Khashab

Kalloo

et al. 2017

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

show abstract

“…A few studies have already proven the concept of a procedureless IGB. Machytka et al published the first report in 2016 [46] and a series of 34 cases one year later [47]. Such studies demonstrated good weight loss outcomes with a tolerable rate of adverse events.…”

Section: Elipsementioning

confidence: 99%

“…That pledge refers to the fact that no endoscopy is necessary for insertion or removal of the balloon. Yet, it requires fluoroscopy to certify the gastric position before inflation [46]. Allurion Technologies have had some exploratory attempts to exempt x-ray using portable ultrasound confirmation, but this is not FDA approved to date.…”

Section: Elipsementioning

confidence: 99%

Gastric space-occupying devices for management of obesity and metabolic disease

Brunaldi

Neto

2020

Techniques and Innovations in Gastrointestinal Endoscopy

View full text Add to dashboard Cite

“…The device is then completely deflated and the balloon is passed in the stool (33). One small study in the Czech Republic showed an EWL of 12.4% at 6 weeks, with no adverse outcomes reported (34). Another study showed improvements in LDL, triglycerides and HbA1c at 6 months.…”

Section: Intragastric Balloonsmentioning

confidence: 99%

Endoscopic bariatric therapies for treating obesity: a learning curve for gastroenterologists

Shahnazarian¹,

Ramai²,

Sarkar³

2019

Transl. Gastroenterol. Hepatol

View full text Add to dashboard Cite

Obesity represents a growing public health threat. Until recently, surgery was the primary means for treating pharmacotherapy resistant obese patients. However, therapeutic endoscopy has evolved as an effective and safe alternative strategy. Particularly, endoscopic bariatric therapy (EBT) can bridge the gap in patients who do not fit the BMI criteria for surgery and fail conservative or medical therapy. Today there are many tools within the realm of EBT available to endoscopists. While there are no formal guidelines for their use, training and use of these tools are limited by the type of institution, preferences of senior endoscopists, cost, and availability. We review different EBT tools available to trainees and gastroenterologist, and the learning curves associated with them.

show abstract

Elipse™, a Procedureless Gastric Balloon for Weight Loss: a Proof-of-Concept Pilot Study

Abstract: This pilot study demonstrates the safety and performance of Elipse™, a procedureless gastric balloon for weight loss. Future studies will test a commercial design filled to 550 mL intended to last in the stomach for at least 12 weeks.

Cited by 57 publications

References 16 publications

Endoluminal weight loss and metabolic therapies: current and future techniques

Endoluminal weight loss and metabolic therapies: current and future techniques

Gastric space-occupying devices for management of obesity and metabolic disease

Endoscopic bariatric therapies for treating obesity: a learning curve for gastroenterologists

Contact Info

Product

Resources

About